

## INTENDED USE

The ZEUS ELISA Rubella IgG Test System is designed for the qualitative and/or quantitative detection of IgG antibodies to rubella virus in human serum. This test is intended to be used to evaluate single sera for immune status or paired sera to demonstrate seroconversion, and is for *In Vitro* diagnostic use.

## SIGNIFICANCE AND BACKGROUND

Rubella is a mild, contagious viral infection that occurs primarily in children and young adults (1, 2). Rubella is characterized by an erythematous maculopapular rash that lasts two or three days. However, greater than 50% of rubella infections are not clinically apparent (2). Other symptoms of rubella may include low grade fever, mild upper respiratory symptoms, and suboccipital lymphadenopathy. Transient arthralgia and arthritis are common symptoms in young adults but more severe complications such as encephalitis or thrombocytopenic purpura are very uncommon (1). Although rubella infection in a child or adult is usually benign and self-limiting, infection of the fetus during the first trimester may cause spontaneous abortion, stillbirth or congenital birth defects (4). Infants infected *in utero* may be born with obvious birth defects or, more commonly, appear normal and either remain normal or develop later complications (1, 2).

Congenital rubella syndrome has long been recognized and is characterized by congenital heart disease, cataracts, neurosensory deafness, mental retardation, and intrauterine growth retardation (1, 4). Following an epidemic of rubella in 1964, other clinical manifestations of congenital rubella were recognized and include neonatal thrombocytopenic purpura, hepatitis, bone lesions and meningoencephalitis (3). Also, diabetes mellitus and progressive rubella panencephalitis are late-emerging manifestations of congenital rubella infection that have recently been recognized (1).

Rubella is endemic worldwide (2). In countries without vaccination programs, 10 - 25% of women of childbearing age are seronegative and susceptible to infection (2). Extensive vaccination programs in the United States and the United Kingdom have greatly reduced the incidence of congenital rubella syndrome (2, 5). Fewer than ten cases per year are now reported in the United States.

The presence of circulating maternal antibody indicates immunity to rubella and virtually excludes the possibility of transmission of rubella to the fetus (2, 5, and 6). If rubella is acquired during pregnancy, particularly during the first trimester, the fetus may be at risk of becoming infected (1). Acute rubella infection can be confirmed by simultaneously testing paired acute and convalescent sera and looking for seroconversion or a fourfold rise in titer, or by the presence of rubella specific IgM (6). The presence of rubella specific IgM in the neonate or the persistence of a high titer of IgG antibody for longer than expected for passively acquired antibody (6 months) confirms a diagnosis of congenital rubella (6).

Hemagglutination inhibition (HAI), the first widely used technique for detection of rubella antibody, has been the reference standard against which newer methods are measured (7). However, the HAI test is labor intensive and difficult to perform since serum samples must be pretreated to remove b-lipoprotein (6, 8). The ELISA (enzyme-linked immunosorbent assay) has been shown to be a sensitive and reliable procedure for detection of antibodies to rubella (8, 9, and 10). ELISA is less cumbersome than HAI and more applicable to screening large numbers of samples, since determinations are made on a single serum dilution which does not require pretreatment. Also, ELISA results are based on an objective absorbency reading which can be correlated with HAI titers (7, 8).

## PRINCIPLE OF THE ASSAY



The ZEUS ELISA Rubella IgG Test System is designed to detect IgG class antibodies to Rubella virus in human sera. Creation of the sensitized wells of the plastic microwell strips occurred using passive adsorption with Rubella antigen. The test procedure involves three incubation steps:

1. Test sera (properly diluted) are incubated in antigen coated microwells. Any antigen specific antibody in the sample will bind to the immobilized antigen. The plate is washed to remove unbound antibody and other serum components.
2. Peroxidase Conjugated goat anti-human IgG is added to the wells and the plate is incubated. The Conjugate will react with IgG antibody immobilized on the solid phase in step 1. The wells are washed to remove unreacted Conjugate.
3. The microwells containing immobilized peroxidase Conjugate are incubated with peroxidase Substrate Solution. Hydrolysis of the Substrate by peroxidase produces a color change. After a period of time the reaction is stopped and the color intensity of the solution depends upon the antibody concentration in the original test sample.

## TEST SYSTEM COMPONENTS

### Materials Provided:

Each Test System contains the following components in sufficient quantities to perform the number of tests indicated on the packaging label. **NOTE: The following components contain Sodium Azide as a preservative at a concentration of <0.1% (w/v): Controls, Calibrator, and SAVE Diluent®.**

Component			Description
PLATE	1	5	Plate: 96 wells configured in twelve, 1x8-well, strips coated with Rubella virus antigen. The strips are packaged in a strip holder and sealed in an envelope with desiccant.
CONJ	1	5	Conjugate: Conjugated (horseradish peroxidase) goat anti-human IgG (Fc chain specific) in 15mL, white-capped bottle(s). Ready to use.
CONTROL +	1	2	Positive Control (Human Serum): 0.35mL, red-capped vial(s).
CAL	1	4	Calibrator (Human Serum): 0.5mL, blue-capped vial(s).
CONTROL -	1	2	Negative Control (Human Serum): 0.35mL, green-capped vial(s).
DIL SPE	1	4	SAVE Diluent®: 30mL, green-capped, bottle(s) containing Tween-20, bovine serum albumin and phosphate-buffered-saline. Ready to use. <b>NOTE: The SAVE Diluent® will change color when combined with serum.</b>
SOLN TMB	1	5	TMB: 15mL, amber-capped, amber bottle(s) containing 3, 3', 5, 5' - tetramethylbenzidine (TMB). Ready to use.
SOLN STOP	1	3	Stop Solution: 15mL, red-capped, bottle(s) containing 1M H <sub>2</sub> SO <sub>4</sub> , 0.7M HCl. Ready to use.
WASHBUF 10X	1	5	Wash Buffer Concentrate (10X): Dilute 1 part concentrate + 9 parts deionized or distilled water. 100mL, clear-capped, bottle(s) containing a 10X concentrated phosphate-buffered-saline and Tween-20 solution (blue solution). <b>NOTE: 1X solution will have a pH of 7.2 ± 0.2.</b>

### NOTES:

1. The following components are not Test System Lot Number dependent and may be used interchangeably with the ZEUS ELISA Test Systems: TMB, Stop Solution, and Wash Buffer. SAVE Diluent® may be used interchangeably with any ZEUS ELISA Test System utilizing Product No. 005CC.
2. Test System also contains a Component Label containing lot specific information inside the Test System box.



## PRECAUTIONS

1. For *In Vitro* diagnostic use.
2. Follow normal precautions exercised in handling laboratory reagents. In case of contact with eyes, rinse immediately with plenty of water and seek medical advice. Wear suitable protective clothing, gloves, and eye/face protection. Do not breathe vapor. Dispose of waste observing all local, state, and federal laws.
3. The wells of the ELISA plate do not contain viable organisms. However, consider the strips **potentially biohazardous materials** and handle accordingly.
4. The Controls are **potentially biohazardous materials**. Source materials from which these products were derived were found negative for HIV-1 antigen, HBsAg and for antibodies against HCV and HIV by approved test methods. However, since no test method can offer complete assurance that infectious agents are absent, handle these products at the Biosafety Level 2 as recommended for any potentially infectious human serum or blood specimen in the Centers for Disease Control/National Institutes of Health manual "Biosafety in Microbiological and Biomedical Laboratories": Current Edition; and OSHA's Standard for Bloodborne Pathogens (13).
5. Adherence to the specified time and temperature of incubations is essential for accurate results. **All reagents must be allowed to reach room temperature (20 - 25°C) before starting the assay.** Return unused reagents to refrigerated temperature immediately after use.
6. Improper washing could cause false positive or false negative results. Be sure to minimize the amount of any residual wash solution; (e.g., by blotting or aspiration) before adding Conjugate or Substrate. Do not allow the wells to dry out between incubations.
7. The SAVE Diluent®, Controls, and Calibrator contain Sodium Azide at a concentration of <0.1% (w/v). Sodium Azide has been reported to form lead or copper azides in laboratory plumbing which may cause explosions upon hammering. To prevent, rinse sink thoroughly with water after disposing of solution containing Sodium Azide.
8. The Stop Solution is TOXIC if inhaled, has contact with skin or if swallowed. It can cause burns. In case of accident or ill feelings, seek medical advice immediately.
9. The TMB Solution is HARMFUL. It is irritating to eyes, respiratory system and skin.
10. The Wash Buffer concentrate is an IRRITANT. It is irritating to eyes, respiratory system and skin.
11. Wipe the bottom of the plate free of residual liquid and/or fingerprints that can alter optical density (OD) readings.
12. Dilution or adulteration of these reagents may generate erroneous results.
13. Do not use reagents from other sources or manufacturers.
14. TMB Solution should be colorless, very pale yellow, very pale green, or very pale blue when used. Contamination of the TMB with Conjugate or other oxidants will cause the solution to change color prematurely. Do not use the TMB if it is noticeably blue in color.
15. Never pipette by mouth. Avoid contact of reagents and patient specimens with skin and mucous membranes.
16. Avoid microbial contamination of reagents. Incorrect results may occur.
17. Cross contamination of reagents and/or samples could cause erroneous results.
18. Reusable glassware must be washed and thoroughly rinsed free of all detergents.
19. Avoid splashing or generation of aerosols.
20. Do not expose reagents to strong light during storage or incubation.
21. Allowing the microwell strips and holder to equilibrate to room temperature prior to opening the protective envelope will protect the wells from condensation.
22. Collect the wash solution in a disposal basin. Treat the waste solution with disinfectant (i.e.: 10% household bleach - 0.5% Sodium Hypochlorite). Avoid exposure of reagents to bleach fumes.
23. Caution: Neutralize any liquid waste at an acidic pH before adding to a bleach solution.
24. Do not use ELISA plate if the indicator strip on the desiccant pouch has turned from blue to pink.
25. Do not allow the Conjugate to come in contact with containers or instruments that may have previously contained a solution utilizing Sodium Azide as a preservative. Residual amounts of Sodium Azide may destroy the Conjugate's enzymatic activity.
26. Do not expose any of the reactive reagents to bleach-containing solutions or to any strong odors from bleach-containing solutions. Trace amounts of bleach (sodium hypochlorite) may destroy the biological activity of many of the reactive reagents within this Test System.

## MATERIALS REQUIRED BUT NOT PROVIDED

1. ELISA microwell reader capable of reading at a wavelength of 450nm. **NOTE: Use of a single (450nm), or dual (450/620 - 650nm), wavelength reader is acceptable. Dual wavelength is preferred, as the additional reference filter has been determined to reduce potential interference from anomalies that may absorb light.** Pipettes capable of accurately delivering 10 - 200µL.
2. Multichannel pipette capable of accurately delivering 50 - 200µL.
3. Reagent reservoirs for multichannel pipettes.
4. Wash bottle or microwell washing system.
5. Distilled or deionized water.
6. One liter graduated cylinder.
7. Serological pipettes.
8. Disposable pipette tips.
9. Paper towels.
10. Laboratory timer to monitor incubation steps.
11. Disposal basin and disinfectant (i.e.: 10% household bleach - 0.5% Sodium Hypochlorite).

## STORAGE CONDITIONS

	Coated Microwell Strips: Immediately reseal extra strips with desiccant and return to proper storage. After opening - strips are stable for 60 days, as long as the indicator strips on the desiccant pouch remains blue.
	Conjugate – DO NOT FREEZE.
	Unopened Test System, Calibrator, Positive Control, Negative Control, TMB, SAVE Diluent®
	Stop Solution: 2 - 25°C Wash Buffer (1X) : 20 - 25°C for up to 7 days, 2 - 8°C for 30 days. Wash Buffer (10X): 2 - 25°C

## SPECIMEN COLLECTION

1. ZEUS Scientific recommends that the user carry out specimen collection in accordance with CLSI document M29: Protection of Laboratory Workers from Infectious Disease (Current Edition).
2. No known test method can offer complete assurance that human blood samples will not transmit infection. Therefore, consider all blood derivatives potentially infectious.
3. Use only freshly drawn and properly refrigerated sera obtained by approved aseptic venipuncture procedures in this assay (11, 14). Do not use if there are any added anticoagulants or preservatives. Avoid using hemolyzed, lipemic, or bacterially contaminated sera.
4. Store sample at room temperature for no longer than 8 hours. If testing is not performed within 8 hours, sera may be stored between 2 - 8°C, for no longer than 48 hours. If a delay in testing is anticipated, store test sera at -20°C or lower. Avoid multiple freeze/thaw cycles which may cause loss of antibody activity and give erroneous results. It is the responsibility of the individual laboratory to use all available references and/or its own studies to determine stability criteria for its laboratory (15).




## ASSAY PROCEDURE

1. Remove the individual components from storage and allow them to warm to room temperature (20 - 25°C).
2. Determine the number of microwells needed. Allow for six Control/Calibrator determinations (one Reagent Blank, one Negative Control, three Calibrators and one Positive Control) per run. Run a Reagent Blank on each assay. Check software and reader requirements for the correct Controls/Calibrator configurations. Return unused strips to the resealable pouch with desiccant, seal, and return to storage between 2 - 8°C.

EXAMPLE PLATE SET-UP		
	1	2
A	Blank	Patient 3
B	Negative Control	Patient 4
C	Calibrator	Etc.
D	Calibrator	
E	Calibrator	
F	Positive Control	
G	Patient 1	
H	Patient 2	

3. Prepare a 1:21 dilution (e.g.: 10µL of serum + 200µL of SAVe Diluent®) of the Negative Control, Calibrator, Positive Control, and each patient serum. **NOTE: The SAVe Diluent® will undergo a color change confirming that the specimen has been combined with the diluent.**
4. To individual wells, add 100µL of each diluted Control, Calibrator and patient specimen. Ensure that the samples are properly mixed. Use a different pipette tip for each sample.
5. Add 100µL of SAVe Diluent® to well A1 as a Reagent Blank. Check software and reader requirements for the correct Reagent Blank well configuration.
6. Incubate the plate at room temperature (20 - 25°C) for 25 ± 5 minutes.
7. Wash the microwell strips 5 times.
  - a. **Manual Wash Procedure:**
    1. Vigorously shake out the liquid from the wells.
    2. Fill each microwell with Wash Buffer. Make sure no air bubbles are trapped in the wells.
    3. Repeat steps 1. and 2. for a total of 5 washes.
    4. Shake out the wash solution from all the wells. Invert the plate over a paper towel and tap firmly to remove any residual wash solution from the wells. Visually inspect the plate to ensure that no residual wash solution remains. Collect wash solution in a disposable basin and treat with disinfectant at the end of the day's run.
  - b. **Automated Wash Procedure:**  
If using an automated microwell wash system, set the dispensing volume to 300 - 350µL/well. Set the wash cycle for 5 washes with no delay between washes. If necessary, the microwell plate may be removed from the washer, inverted over a paper towel and tapped firmly to remove any residual wash solution from the microwells.
8. Add 100µL of the Conjugate to each well, including the Reagent Blank well, at the same rate and in the same order as the specimens.
9. Incubate the plate at room temperature (20 - 25°C) for 25 ± 5 minutes.
10. Wash the microwells by following the procedure as described in step 7.
11. Add 100µL of TMB to each well, including the Reagent Blank well, at the same rate and in the same order as the specimens.
12. Incubate the plate at room temperature (20 - 25°C) for 10 - 15 minutes.
13. Stop the reaction by adding 50µL of Stop Solution to each well, including the Reagent Blank well, at the same rate and in the same order as the TMB. Positive samples will turn from blue to yellow. After adding the Stop Solution, tap the plate several times to ensure that the samples are thoroughly mixed.
14. Set the microwell reader to read at a wavelength of 450nm and measure the optical density (OD) of each well against the Reagent Blank. Read the plate within 30 minutes of the addition of the Stop Solution.

### ABBREVIATED TEST PROCEDURE

1. Dilute Serum 1:21.
2. Add diluted sample to microwell - 100µL/well.
3.  Incubate 25 ± 5 minutes.
4. Wash.
5. Add Conjugate - 100µL/well.
6.  Incubate 25 ± 5 minutes.
7. Wash.
8. Add TMB - 100µL/well.
9.  Incubate 10 - 15 minutes.
10. Add Stop Solution - 50µL/well - Mix.
11. READ within 30 minutes.

## QUALITY CONTROL

1. Each time the assay is performed, the Calibrator must be run in triplicate. A Reagent Blank, Negative Control, and Positive Control must also be included.
2. Calculate the mean of the three Calibrator wells. If any of the three values differ by more than 15% from the mean, discard that value and calculate the mean using the remaining two wells.
3. The mean OD value for the Calibrator, Positive Control, and Negative Control should fall within the following ranges:

	OD Range
Negative Control	≤0.250
Calibrator	≥0.300
Positive Control	≥0.500

- a. The OD of the Negative Control divided by the mean OD of the Calibrator should be ≤0.9.
  - b. The OD of the Positive Control divided by the mean OD of the Calibrator should be ≥1.25.
  - c. If the above conditions are not met the test should be considered invalid and should be repeated.
4. The Positive Control and Negative Control are intended to monitor for substantial reagent failure, but will not ensure precision at the assay Cutoff.
  5. Additional Controls may be tested according to guidelines or requirements of local, state, and/or federal regulations or accrediting organizations.
  6. Refer to CLSI document C24: Statistical Quality Control for Quantitative Measurement Procedures for guidance on appropriate QC practices.

## INTERPRETATION OF RESULTS

1. **Calculations:**
  - a. **Correction Factor:** The manufacturer determined a Cutoff OD Value for positive samples and correlated it to the Calibrator. The Correction Factor (CF) allows for the determination of the Cutoff Value for positive samples. It will also correct for slight day-to-day variations in test results. The Correction Factor is determined for each lot of components and is printed on the Component Label located in the Test System box.

- b. **Cutoff OD Value:** To obtain the Cutoff OD Value, multiply the CF by the mean OD of the Calibrator determined above.  
( $CF \times \text{Mean OD of Calibrator} = \text{Cutoff OD Value}$ )
- c. **Index Values/OD Ratios:** Calculate the Index Value/OD Ratio for each specimen by dividing its OD Value by the Cutoff OD from step b.

Example:

Mean OD of Calibrator	=	0.793
Correction Factor (CF)	=	0.25
Cutoff OD	=	$0.793 \times 0.25 = 0.198$
Unknown Specimen OD	=	0.432
Specimen Index Value/OD Ratio	=	$0.432/0.198 = 2.18$

2. **Interpretations:** Index Values/OD Ratios are interpreted as follows.

	Index Value/OD Ratio
Negative Specimens	$\leq 0.90$
Equivocal Specimens	0.91 - 1.09
Positive Specimens	$\geq 1.10$

- a. An OD ratio  $\leq 0.90$  indicates no significant amount of IgG antibodies to the rubella virus. A negative result indicates no current or previous infection with the rubella virus. Presume that such individuals are susceptible to primary infection. However, specimens taken too early during a primary infection may not have detectable levels of IgG antibody. If a primary infection is suspected, another specimen should be taken in eight to 14 days and tested concurrently in the same assay with the original specimen to look for seroconversion.
- b. An OD ratio  $\geq 1.10$  indicates that IgG antibodies specific to Rubella were detected. A positive test result indicates a previous infection with the rubella virus. Such individuals are presumed to be at risk of transmitting rubella virus infection, but are not necessarily currently contagious.
- c. Specimens with OD ratio values in the equivocal range (0.91 - 1.09) should be retested in duplicate. Report any two of the three results which agree. Evaluate repeatedly equivocal specimen using an alternate serological method and/or re-evaluate by drawing another sample one to three weeks later.
- d. To evaluate paired (acute and convalescent) sera, both samples must be tested in the same assay. If the acute specimen is negative and the convalescent specimen is positive, seroconversion has taken place and a primary rubella virus infection is indicated.
3. **Conversion of OD Ratio to IU/mL:** As an option, OD ratios may be converted to IU/mL by multiplying the OD ratio by 9.091. IU/mL values may then be interpreted as follows:

	IU/mL
Negative Specimens	$\leq 8.18$
Positive Specimens	$\geq 10.0$
Equivocal Specimens	8.19 - 9.99

Interpretation criteria for positive, negative, and equivocal specimens are as stated above. **NOTE: The assay is linear and correlates well with the WHO Standard between 0 and 20 IU/mL.** Specimens producing a result greater than 20 IU/mL should be reported as "positive", or "> 20 IU/mL". If greater accuracy is required, the specimen must be diluted and re-tested. The final result may be found by multiplying the resulting IU/mL value by the dilution factor.

Example:

Initial Result: Ratio = 2.68 = 24.34 IU/mL  
Dilute 1:2 in SAVE Diluent\*; then, 1:21 as the procedure indicates.  
Re-test Result: Ratio = 1.88 = 17.09 IU/mL  $\times 2 = 34.18$  IU/mL

### LIMITATIONS OF THE ASSAY

- Do not use the antibody titer of a single serum specimen to determine recent infection. Collect paired samples (acute and convalescent) and test concurrently to demonstrate seroconversion.
- Interpret test results in conjunction with the clinical evaluation and the results of other diagnostic procedures.
- Samples collected too early in the course of an infection may not have detectable levels of IgG. In such cases, a second sample may be collected after two to seven weeks and tested concurrently with the original specimen to look for seroconversion or an IgM specific assay should be performed.
- Interpret a positive rubella IgG test in neonates with caution, since passively acquired maternal antibody can persist for up to six months (6). However, a negative test for IgG antibody in the neonate may help exclude congenital infection (12).

### EXPECTED RESULTS

Seroepidemiologic studies indicate that in most countries 80 - 90% of the adult population have detectable antibodies to rubella (2).

### PERFORMANCE CHARACTERISTICS

#### 1. Comparative Study

An in-house comparative study was performed to demonstrate the equivalence of the ZEUS Rubella IgG ELISA Test System to another ELISA procedure for detection of IgG antibodies to rubella virus. The ZEUS Rubella ELISA Test System showed 100% agreement with the other procedure. These results are summarized below:

ZEUS ELISA Rubella IgG Test System	Reference Rubella IgG ELISA		
		Positive	Negative
	Positive	262	0
	Negative	0	141
	Equivocal	4	5

#### 2. Evaluation of the WHO Reference Standard

A study was conducted in-house to evaluate the recovery of the WHO Standard using the ZEUS assay. The results of this investigation are shown below:

Standard (IU/mL)	Result		Interpretation
	Ratio	IU/mL	
640	4.60	546.88*	Positive
320	4.49	273.44*	Positive
160	4.25	136.72*	Positive
80	3.20	68.36*	Positive
40	2.68	34.18*	Positive
20	1.88	17.09	Positive
10	1.19	10.82	Positive
5	0.68	6.16	Negative
2.5	0.31	2.78	Negative

\* Specimens were initially >20 IU/mL. Required additional dilutions to accurately determine the unit value.

### 3. Reproducibility

To assess intra- and inter-assay variation of the ZEUS ELISA Rubella IgG Test System, a reproducibility study was performed using three specimens with OD ratio values in the high positive, low positive, and negative ranges. Eight replicates of each sample were run on three consecutive days. The mean OD ratio and coefficient of variation (CV) were calculated for each sample. These data are shown below:

	Intra-Assay (n=8)						Inter-Assay (n=3)	
	Run 1		Run 2		Run 3			
	Mean Ratio	% CV	Mean Ratio	% CV	Mean Ratio	% CV	Mean Ratio	%C V
Serum 1	0.65	6.2	0.62	8.7	0.72	5.1	0.66	6.3
Serum 2	1.33	13.2	1.45	7.3	1.26	6.8	1.35	5.8
Serum 3	4.44	4.4	3.72	4.4	4.56	8.9	4.24	8.7

### REFERENCES

1. Cooper LZ: The history and medical consequences of rubella. Rev. Infect. Dis. 7:502-510, 1985.
2. Assad F and Ljungars-Esteves K: Rubella - world impact. Rev. Infect. Dis. 7:529-536, 1985.
3. Cooper LZ, Green RH, Krugman S, Giles JP, and Mirick GS: Neonatal thrombocytopenic purpura and other manifestations of rubella contracted *in utero*. Am. J. Dis. Child. 110:416-427, 1965.
4. Miller E, Cradock-Watson JE, and Pollock TM: Consequences of confirmed maternal rubella at successive stages of pregnancy. Lancet 2:781-784, 1982.
5. Hinman AR, Bart KJ, Orenstein WA, and Preblud SR: Rational strategy for rubella vaccination. Lancet 1:39-41, 1983.
6. Herrman KL: Rubella virus In: Lennette EH, Balows A, Hausler WJ, and Shadomy HJ, eds., Manual of Clinical Microbiology, American Society for Microbiology, Washington, DC, Ch. 76, pp. 779-784, 1985.
7. Herman KL: Available rubella serologic tests. Rev. Infect Dis. 7:5108-5112, 1985.
8. Vaheri A and Salonen EM: Evaluation of solid-phase enzyme-immunoassay procedure in immunity surveys and diagnosis of rubella. J. Med. Virol. 5:171-181, 1980.
9. Enders G: Serologic test combinations for safe detection of rubella infections. Rev. Infect. Dis. 7:5113-5122, 1985.
10. Steece RS, Talley MS, Skeels MR, and Lanier GA: Comparison of enzyme-linked immunosorbent assay, hemagglutination inhibition, and passive latex agglutination for determination of rubella immune status. J. Clin. Micro. 21:140-142, 1985.
11. Procedures for the Handling and Processing of Blood Specimens: NCCLS Procedure H18. Approved guideline.
12. Chernesky MA, Ray CG, and Smith TF: Laboratory diagnosis of viral infections. Cumitech 15, American Society for Microbiology, Washington, DC, 1982.
13. U.S. Department of Labor (OSHA): Occupational Exposure to Bloodborne Pathogens. Final Rule. 21CFR 1910.1030.
14. Procedures for the collection of diagnostic blood specimens by venipuncture: NCCLS Procedure H3, Approved Standard.
15. Procedures for the Handling and Processing of Blood Specimens for Common Laboratory Tests; Approved Guidelines – 4<sup>th</sup> Edition (2010). CLSI Document GP44-A4 (ISBN 1-56238-724-3). Clinical and Laboratory Standards Institute, 950 West Valley Road, Suite 2500, Wayne, PA 19087.



**ZEUS Scientific**  
200 Evans Way, Branchburg, New Jersey, 08876, USA  
Toll Free (U.S.): 1-800-286-2111, Option 2  
International: +1 908-526-3744  
Fax: +1 908-526-2058  
Website: [www.zeusscientific.com](http://www.zeusscientific.com)  
ZEUS ELISA and SAVE Diluent® are trademarks of ZEUS Scientific

For US Customer Service contact your local distributor.  
For US Technical Support contact ZEUS Scientific, call toll free  
or e-mail [support@zeusscientific.com](mailto:support@zeusscientific.com).  
For Non-US Customer Service and Technical Support inquiries,  
please contact your local distributor.

© 2017 ZEUS Scientific All Rights Reserved.